title: Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments.
abstract: Liver metastases of colorectal cancer is present in more than 20% of new diagnosed patients and in 40-60% of relapsed patients. It is a life-threatening prognostic aspect. Hepatic resection, when possible, is the best therapeutic modality, although the overall survival rate is still low (30%). Angiography and intraoperative ultrasonography are useful for resection. The number of hepatic metastases and the surgical margin are probably the most significant prognostic factors. Colorectal cancer may spread predominantly to the liver making regional treatment strategies viable options. Subtotal hepatic resections and segmentectomies are potentially curable procedures for single or small numbers of hepatic metastases without other sites of disease. However, there have been no prospective randomized trials comparing patients with unresected liver metastases and resected metastases. Regional chemotherapy with floxuridine seems usefull combined with hepatic resection or as palliative therapy. Gastric ulcer and biliary sclerosis are the main related toxicities. Patients with localized, unresectable hepatic metastases or concomitant bad medical condition may be candidates for radiation, percutaneous ethanol injection, cryosurgery, percutaneous radiofrequency, hypoxic flow-stop perfusions with bioreductive alkylating agents, hepatic arterial ligation, embolization and chemoembolization. These new hepatic-directed modalities of treatment are being investigated and may offer new approaches to providing palliation and prolonging survival. This review will report the possibilities of intra-arterial chemotherapy and other novel hepatic-directed approaches to the treatment of liver metastases from colorectal cancer.
authors.affiliation: Department of Oncology and Hematology, City Hospital, Ravenna, Italy. g.fiorentini@iol.it
authors.forename: G
authors.initials: G
authors.lastname: Fiorentini
authors.forename: D B
authors.initials: DB
authors.lastname: Poddie
authors.forename: U
authors.initials: U
authors.lastname: De Giorgi
authors.forename: D
authors.initials: D
authors.lastname: Guglielminetti
authors.forename: P
authors.initials: P
authors.lastname: Giovanis
authors.forename: M
authors.initials: M
authors.lastname: Leoni
authors.forename: W
authors.initials: W
authors.lastname: Latino
authors.forename: C
authors.initials: C
authors.lastname: Dazzi
authors.forename: A
authors.initials: A
authors.lastname: Cariello
authors.forename: D
authors.initials: D
authors.lastname: Turci
authors.forename: M
authors.initials: M
authors.lastname: Marangolo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D003452:Cryosurgery; D004621:Embolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000431:Ethanol